Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-month, randomised double-blind, placebo controlled, international, multicentre study.

Trial Profile

Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-month, randomised double-blind, placebo controlled, international, multicentre study.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Apr 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EDIFY
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 30 Apr 2017 Primary endpoint (Echo-Doppler E/e ratio) has not been met, according to the results published in the European Journal of Heart Failure
    • 30 Apr 2017 Primary endpoint (B-type natriuretic peptide levels (NT-proBNP)) has not been met, according to the results published in the European Journal of Heart Failure
    • 30 Apr 2017 Primary endpoint (Six-minute walking distance) has not been met, according the results published in the European Journal of Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top